PM Cares funded 500-bed DRDO Covid hospital in Srinagar, admitting patients now
India | June 12, 2021 12:55 ISTA 500-bed COVID hospital set up using funds from PMCARES Fund has started admitting patients now.
A 500-bed COVID hospital set up using funds from PMCARES Fund has started admitting patients now.
2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories.
Of the total 500 beds at Bhagwati Nagar Centre, 125 would be Intensive Care Unit (ICU) beds, while others would be a set of Covid beds with 24 hours oxygen facility.
The Covid Care Centre has been dedicated and named after General Bipin Chandra Joshi, PVSM, AVSM, ADC who belonged to state of Uttarakhand and was the 17th Chief of Indian Army.
2-DG is an oral anti-viral drug for Covid-19 patients. It has been developed by the DRDO in collaboration with Dr Reddy's Laboratories. It reduces dependence on supplemental oxygen.
Of the total 500 beds here at Bhagwati Nagar Centre, 125 would be Intensive Care Unit beds, while others would be a set of Covid beds with 24 hours oxygen facility.
The price of DRDO’s 2DG anti-COVID 19 drug has been fixed at Rs 990 per sachet by Dr Reddy’s lab.
The DIPCOVAN kit can detect both spike as well as nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97% and specificity of 99%.
India's first indigenous anti-COVID drug 2-DG is a "repurposed" medicine, the Indian Council of Medical Research said on Thursday. According to ICMR DG Dr. Balram Bhargava, the drug was earlier used for cancer treatment.
Dr Reddy's on Wednesday released important information regarding drug 2-deoxy-D-glucose (2DG), developed by INMAS, a DRDO lab in collaboration with Dr. Reddy’s Laboratories.
Haryana on Monday reported 114 COVID deaths and 7,488 fresh cases, taking the state’s fatality count to 6,799 and the total infection number to 7,01,915, according to a Health Department bulletin.
The first batch of 2-deoxy-D-glucose (2-DG) drug developed by the Defence Research and Development Organisation (DRDO) for treatment of Covid-19 was released by Defence Minister Rajnath Singh on Monday. The medicine is being touted as a game-changer in the fight against COVID.
The first batch of drug 2-deoxy-D-glucose drug to treat Covid-19 patients will be launched today. The drug has been developed by the Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy's Laboratories (DRL).
The 2-DG (2-deoxy-D-glucose) is an anti-COVID-19 therapeutic application of the drug. It has been developed by DRDO and Dr Reddy's Laboratories.
"The two aircraft carrying zeolite from Rome arrived as the first consignment of the key component," a DRDO official told IANS.
The first batch of anti-COVID drug 2-DG, developed by the DRDO, will be released on Monday (May 17) by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan, officials said.
At a time when country battles with the second wave of coronavirus, the first batch of 10,000 doses of 2DG medicine for curing COVID-19 patients would be launched early next week and will be given to patients, DRDO officials informed on Friday.
The 2-DG drug developed by the Defence Research and Development Organisation (DRDO) could be a game-changer in the fight against COVID, Karnataka Health Minister Dr K Sudhakar said on Friday.
The recruitment drive is being conducted for 79 vacancies. The candidates can apply through the website- drdo.gov.in
The government on Wednesday approved the procurement of 1,50,000 units of 'Oxycare' system developed by the Defence Research and Development Organisation (DRDO) to help in the treatment of COVID-19 patients.
Top News
Latest News
